WGRX News & Events

Wellgistics Health announced that its Executive Chairman Suren Ajjarapu and President & Interim Co-CEO Prashant Patel have exercised all warrants previously issued to them in connection with the conversion of their outstanding salaries into common shares at $10 per share. The exercise of the warrants resulted in the issuance of a total of 200,000 to the executives. Following the exercise of these warrants, Wellgistics confirms that as of the date of this press release there are 2,847,198 common shares outstanding. Certain stockholders holding approximately 1,533,930 common shares, representing a majority of the outstanding common shares, have entered into lock-up agreements that preclude the sale of their shares into the market for at least ninety days from today's date.

Wellgistics Health announced that its management and Board of Directors has selected DataMeds AI, Inc as its new corporate name, subject to shareholder approval. The proposed new stock sticker remains MEDS. A preliminary proxy was filed on Thursday, June 18 with the U.S. Securities & Exchange Commission requesting shareholder approval to effect the name change. The DataMeds AI, Inc. name was advanced to replace the name DelivMeds AI, Inc. that was previously announced as the projected Wellgistics Health, Inc. corporate name. Concurrent with this announcement, Wellgistics also announced that it is changing the name of its Pharmacy and Pharmacy Services division to Corexa Health. Wellgistics confirms that as of the date of this press release there are 2,647,198 common shares outstanding. Certain stockholders holding approximately 1,333,930 common shares, representing a majority of the outstanding common shares, have entered into lock-up agreements that preclude the sale of their shares into the market for at least ninety days from today's date. There are currently 919,465 shares of Wellgistics common stock deposited in Depository Trust & Clearing Corporation available for trading. There are no debt or preferred equity securities of the Company that are eligible to convert into free trading common shares at the current time. There is a total of 80,826 cash warrants outstanding, each with a fixed exercise price of $35.00 per share, that are currently eligible to be exercised into free trading common shares. Investors should refer to the Company's filings with the Securities and Exchange Commission for additional information regarding the Company's capitalization and outstanding securities. The Board is evaluating the previously announced Dream Bowl 2026 Meme Coin Token distribution and expects to provide additional information, if any, at an appropriate time.

Wellgistics Health provided a mid-year 2026 corporate outlook. The Company intends to focus on closing the recently announced DelivMeds AI transaction, continuing to drive quarter-over-quarter growth through its Wellgistics Pharmacy business unit, and supporting the continued progress in the three key aspects of the DelivMeds AI transaction: PharmacyChain progress, Medical Drones implementation and Health Lives Here launch scheduled for the third quarter of 2026. "The last two weeks have been transformative for the Company from a strategic direction, financial structure and funding standpoint," said Interim Co-CEO Gerald Commissiong. "With the reverse split that was required to maintain our NASDAQ listing now behind us, and with the support of holders of a majority of our common shares limiting the supply of common shares available to trade through the lock-up agreement announced last Thursday that leaves approximately 1.3 million shares available to trade based on the Company's current estimates, the Company is now positioned for significant growth in the months ahead. New shares from the financing will not be eligible for resale until they are issued in accordance with the transaction documents and either registered for resale under an effective registration statement or eligible for resale under Rule 144 or another applicable exemption, expected in the third quarter. We expect our previously announced joint venture with KareRx to continue to increase our monthly pharmacy sales and are looking forward to establishing new manufacturer relationships as a result of the DelivMeds AI business model. With an expeditious closing of the DelivMeds AI transaction squarely in focus, we believe the addition of the 'all-of-healthcare' smart contracts claims to our exclusive PharmacyChain blockchain intellectual property stack is poised to significantly expand the Company's relationship with DataVault AI by making it one of Wellgistics' largest shareholders while allowing us to apply the full power of our proprietary EinsteinRx artificial intelligence decision-making technology beyond our current pharmacy-only license. The recently announced QOLPOM IP acquisition, once closed, will allow us to immediately integrate biometric confirmation of a drug's pharmacodynamic effect to begin to objectively confirm prescription use adherence within the Health Lives Here consumer app that is targeted for launch at the 2026 Pro Football Hall of Fame game in Canton, OH in August, while also setting the stage for the coming disruption of the pharmaceuticals and medical supplies delivery sector with biometric confirmation-enabled medical drones. The Health Lives Here app itself is currently being optimized for that launch, with telemedicine, telelabs and telepharmacy features being added to its unique mental health AI technology in order to tailor coaching and regimen compliance messaging around which the app itself is centered to help patients reach and maintain their health goals. All of these innovations are being built for the launch of Tollo Health's proprietary nutraceutical products starting with Forzet, a proprietary medical food positioned as an adjunct to GLP-1 agonist drugs to help limit muscle loss. We know that next-generation GLP-1 agonist product candidates in the pipeline are already being positioned to help mitigate muscle loss, and we believe that given Forzet's mechanism of action it will further enhance those drugs' benefit to patients. We also intend to focus on the underserved areas of active viral infections with Galectovid and Long COVID with Tollovid. We believe strongly that the COVID pandemic catalyzed an already-emerging trend of Americans seeking non-pharmaceutical solutions to help improve and maintain healthy immune function, while building muscle. Tollo Health's best-in-breed product pipeline integrated with Wellgistics' pharmacist-led patient-engagement philosophy elevates that message, especially as part of an overall healthcare messaging paradigm being advanced together with NFL Alumni."